公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2012 | Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity | Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 72 | 70 | |
2013 | Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells | Liu C.-Y.; Shiau C.-W.; Kuo H.-Y.; HSIANG-PO HUANG ; Chen M.-H.; Tzeng C.-H.; Chen K.-F. | Haematologica | 39 | 37 | |
2013 | Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome | Yu H.-C.; Hou D.-R.; Liu C.-Y.; Lin C.-S.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F. | PLoS ONE | 41 | 93 | |
2014 | CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation | Wang C.-Y.; Chao T.-T.; Chang F.-Y.; Chen Y.-L.; Tsai Y.-T.; Lin H.-I.; Huang Y.C.T.; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Lung Cancer | 29 | 25 | |
2018 | Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023)) | Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 1 | 1 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 1 | 1 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 0 | 1 | |
2006 | Development of small-molecule cyclin D1-ablative agents | Huang J.-W.; Shiau C.-W.; Yang J.; Wang D.-S.; HAO-CHIEH CHIU ; Chen C.-Y.; Chen C.-S. | Journal of Medicinal Chemistry | 52 | 48 | |
2014 | Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma | Tai W.-T.; Shiau C.-W.; PEI-JER CHEN ; Chu P.-Y.; HSIANG-PO HUANG ; Liu C.-Y.; Huang J.-W.; Chen K.-F. | Hepatology | 63 | 59 | |
2016 | Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis | Su J.-C.; Mar A.-C.; Wu S.-H.; Tai W.-T.; Chu P.-Y.; Wu C.-Y.; Tseng L.-M.; Lee T.-C.; Chen K.-F.; Liu C.-Y.; HAO-CHIEH CHIU ; Shiau C.-W. | Scientific Reports | 44 | 34 | |
2012 | Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3 | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; PEI-JER CHEN ; Chen K.-F. | Molecular Cancer Therapeutics | 112 | 108 | |
2016 | In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA | Chang H.-C.; YU-TSUNG HUANG ; Chen C.-S.; Chen Y.-W.; Su J.-C.; LEE-JENE TENG ; Shiau C.-W.; HAO-CHIEH CHIU | Journal of Antimicrobial Chemotherapy | 25 | 22 | |
2012 | Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells | Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN ; ANN-LII CHENG | Biochemical Pharmacology | 50 | 50 | |
2013 | Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma | Yu H.-C.; Chen H.-J.; Chang Y.-L.; Liu C.-Y.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F. | Biochemical Pharmacology | 45 | 44 | |
2019 | Loxapine, an antipsychotic drug, suppresses intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages | Yang C.-Y.; Hsu C.-Y.; Fang C.-S.; Shiau C.-W.; Chen C.S.; HAO-CHIEH CHIU | Journal of Microbiology, Immunology and Infection | 11 | 10 | |
2013 | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells | Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; ANN-LII CHENG ; PEI-JER CHEN ; Chen K.-F. | Cell Death and Disease | 159 | 159 | |
2013 | SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells | CHEN-TI WANG ; Lin C.-S.; Shiau C.-W.; Chu P.-Y.; Hsiao C.-C.; Chiang Y.-L.; Tai W.-T.; Chen K.-F. | Journal of Orthopaedic Research | 9 | 6 | |
2014 | SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model | Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN ; Chen K.-F. | Molecular Cancer Therapeutics | 7 | 6 | |
2014 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer | Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN ; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Journal of Thoracic Oncology | 11 | 11 | |
2011 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; HSIANG-PO HUANG ; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 146 | 140 |